Table 2 Baseline demographic and clinical characteristics
Characteristic | Lenalidomide arm (N = 13) | Ibrutinib arm (N = 13) | Total (N = 26) |
|---|---|---|---|
Age (years), median (range) | 53 (36–60) | 52 (32–60) | 52 (32–60) |
Sex ratio, M/F | 1.2 | 2.25 | 1.6 |
KPS (%), median (range) | 80 (50–100) | 80 (40–100) | 80 (40–100) |
Symptoms at diagnosis Motor/sensory deficit, N(%) Cognitive impairment, N(%) Gait disorder, N(%) Headache/intracranial hypertension, N(%) | 5 (38.5%) 5 (38.5%) 2 (15.4%) 2 (15.4%) | 4 (30.8%) 3 (23.1%) 2 (15.4%) 2 (15.4%) | 9 (34.6%) 8 (30.8%) 4 (15.4%) 4 (15.4%) |
Elevated serum LDH, N(%) | 3 (23.1%) | 8 (61.5%) | 11 (42.3%) |
Diagnostic method Cerebral biopsy, N(%) CSF analysis, N(%) CSF analysis + vitrectomy, N(%) | 13 (100%) 0 (0%) 0 (0%) | 11 (84.6%) 1 (7.7%) 1 (7.7%) | 24 (92.3%) 1 (3.8%) 1 (3.8%) |
MRI Contrast enhancement, N(%) Unique vs. multiple/diffuse lesions, N(%) Infratentorial involvement, N(%) | 13 (100%) 3 (23.1%) vs. 9 (69.2%) 3 (23.1%) | 13 (100%) 7 (53.8%) vs. 6 (46.2%) 1 (7.7%) | 26 (100%) 10 (38.5%) vs. 15 (57.7%) 4 (15.4%) |
CSF analysis Done, N(%) Lymphomatous meningitis (positive cytology and/or flow cytometry), N(%) | 10 (76.9%) 3 (30%) | 12 (92.3%) 6 (50%) | 22 (84.6%) 9 (40.9%) |
Ophthalmologic examination Done, N(%) Ocular involvement, N(%) | 12 (92.3%) 1 (8.3%) | 13 (100%) 3 (23.1%) | 25 (96.2%) 4 (16%) |